Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.0	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.0	0.499	0.01	NA	NA	0.499
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.0	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.0	0.547	0.01	NA	NA	0.547
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.0	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.0	0.6	0.01	-13.0	1.0	0.6
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	0.0	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.0	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.0	0.604	0.01	-3.02	1.0	0.621
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
HCC1806	Buparlisib	2	72	sigmoid	sigmoid	HCC1806 buparlisib 0 2 72	8	2.827	0.759	-0.346	0.221	0.937	-0.392	2.75	1.0	2.72e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	Buparlisib	3	72	sigmoid	sigmoid	HCC1806 buparlisib 0 3 72	8	3.195	0.808	-0.257	0.203	0.96	-0.303	2.74	1.0	2.03e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	Buparlisib	1	72	sigmoid	sigmoid	HCC1806 buparlisib 0 1 72	8	2.742	0.748	-0.369	0.226	0.931	-0.415	2.75	1.0	2.95e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
BT-549	GDC-0980	1	72	sigmoid	sigmoid	BT549 apitolisib 0 1 72	8	1.781	0.19	0.113	0.333	0.16	0.1	1.27	0.999	4.05e-10	NA	0.328	0.352	0.744	0.132	0.347	1.31	0.999	7.05e-10	NA
HCC38	BX-912	2	72	sigmoid	sigmoid	HCC38 BX-912 0 2 72	8	2.186	0.583	-0.229	0.251	0.648	-0.233	3.62	0.999	9.58e-10	NA	0.602	0.124	0.807	0.559	0.123	3.78	0.998	1.03e-08	NA
Hs 578T	Torin1	2		sigmoid	sigmoid	Hs578T Torin1 2	8	2.548	0.0205	0.144	0.566	0.0148	0.14	1.0	0.999	3.13e-10	NA	0.0182	0.241	0.463	0.00975	0.24	1.04	0.999	6.11e-10	NA
Hs 578T	PI103	2		sigmoid	sigmoid	Hs578T PI-103 2	8	2.503	0.223	-0.0213	0.356	0.303	-0.15	0.858	0.999	7.33e-10	NA	0.206	0.167	0.661	0.152	0.121	0.921	0.999	1.9e-09	NA
Hs 578T	AZD8055	2		sigmoid	sigmoid	Hs578T AZD8055 2	8	2.480	0.0521	0.149	0.469	0.0387	0.142	1.13	0.999	3.49e-10	NA	0.0495	0.253	0.557	0.0273	0.249	1.16	0.999	4.45e-10	NA
HCC38	BX-912	1	72	sigmoid	sigmoid	HCC38 BX-912 0 1 72	8	1.760	0.529	-0.322	0.274	0.591	-0.322	4.49	0.999	1.36e-10	NA	0.584	0.149	0.818	0.541	0.149	4.63	0.999	8.39e-10	NA
HCC38	Buparlisib	1	72	sigmoid	sigmoid	HCC38 buparlisib 0 1 72	8	1.738	0.912	-0.226	0.194	1.46	-0.57	1.62	0.999	9.48e-10	NA	1.2	0.192	0.858	1.12	0.0495	1.66	0.998	4.36e-09	NA
HCC1806	BX-912	3	72	sigmoid	sigmoid	HCC1806 BX-912 0 3 72	8	3.193	1.09	0.234	0.126	0.897	0.217	2.99	0.999	2.85e-09	NA	0.894	0.214	0.853	0.753	0.205	3.07	0.997	2.86e-08	NA
HCC1806	BX-912	2	72	sigmoid	sigmoid	HCC1806 BX-912 0 2 72	8	2.825	0.992	0.159	0.14	0.888	0.141	2.99	0.999	3.32e-09	NA	0.894	0.214	0.854	0.753	0.205	3.07	0.997	2.86e-08	NA
Hs 578T	Torin1	3		sigmoid	sigmoid	Hs578T Torin1 3	8	2.860	0.0307	0.174	0.514	0.0196	0.176	0.964	0.999	2.01e-09	NA	0.0212	0.218	0.469	0.0119	0.222	1.02	0.998	1.17e-08	NA
HCC38	Torin1	3	72	sigmoid	sigmoid	HCC38 Torin1 0 3 72	8	1.441	0.0231	-0.202	0.666	0.0412	-0.248	0.698	0.999	5.79e-10	NA	0.0787	0.266	0.572	0.0306	0.245	0.714	0.999	5.55e-10	NA

<
<<
Previous
Page 1 of 18
Next
>>
>
1 to 25 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)